The report titled “Ischemic strokes Market -Forecast to 2023″ is a direct appreciation by
Market Research Future of the market potential of the Micro Guide Catheters Market.
Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to
the brain. The underlying condition of this type of obstruction is the development of fat
deposits lining the vessel walls, which is known as atherosclerosis. According to the World
Health Organization (WHO), stroke accounts for around 17 million deaths annually. As per
the Centers for Disease Control and Prevention (CDC), stroke leads to 1 out of every 20
deaths costing around USD 34 billion each year in the U.S. Higher rates of mortality
associated with strokes highlight an impending need for innovative drugs and diagnostic
devices.
The key strategies adopted by leading industry players incldues new product launches and
collaborations. For instance, in April 2016, the novel TransCarotid Artery Revascularization
(TCAR) procedure launched by Silk Road Medical, Inc, received FDA approval. This
minimally invasive technique is designed to access the common carotid artery. Moreover, in
March, 2015, WATCHMAN, a closure device designed to prevent stroke in patients with atrial
fibrillation received FDA approval.
Rising cases of ischemia stroke are driving the demand for surgical procedures in stroke
treatment. Increasing demand for minimally invasive procedures and advancements in
surgical procedures are the key factors boosting the growth of the global ischemic stroke
market. High cost of the surgical procedures and excessive usage of medication for the
treatment of ischemic stroke are hindering the market growth.
The Global Ischemic Stroke Market is expected to grow at a CAGR of approximately 8.3%
during the forecast period 2017-2023.
Segmentation:
The ischemic stroke is segmented on the basis of diagnosis, drug class, surgery and end-
users.
On the basis of the diagnosis, the market is segmented into Computed Tomography (CT),
Magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography,
electrocardiography, echocardiography, and others.
On the basis of the drug class, the market is segmented into tissue plasminogen activator,
anticoagulant, antiplatelet, antihypertensive, and others
On the basis of the surgery, the market is segmented into carotid endarterectomy,
angioplasty, and endovascular mechanical thrombectomy
On the basis of the end-user, the market is segmented into hospitals & clinics, medical
institutes, research organization, and others.
Key Players:
The emergence of new and cost-effective medication options for the treatment of ischemic
stroke could open up new opportunities to the new players in the Global Ischemic Stroke
Market. Additionally, emerging markets, such as India and China, could also open new
opportunities to new players.
Some of key the players in the Americas ischemic stroke market are Abbott Laboratories
(U.S.), Medtronic plc (U.S.), Boston Scientific Corporation (U.S.), Cordis Corporation
(U.S.), Koninklijke Philips N.V. (Netherland), GE Healthcare (U.S.), Stryker Corporation
(U.S.), Genentech, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Boehringer
Ingelheim (Germany), Sanofi (France), Covidien plc (Ireland), Philips Healthcare (U.S.),
Johnson & Johnson (U.S.), Penumbra, Inc. (U.S.), GE Healthcare (U.S.), Siemens
Healthcare (U.S.), Hitachi, Ltd (Japan), Biogen (U.S.), Daiichi Sankyo (U.S.), Pfizer Inc.
(U.S.), and others
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5423 .
Regional Analysis:
The Global Ischemic Stroke Market consists of countries namely America, Europe, Asia
Pacific, and the Middle East and Africa.